Latest & greatest articles for doxycycline

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on doxycycline or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on doxycycline and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for doxycycline

1. Doxycycline may be a safer first option for treating a blistering skin condition

Doxycycline may be a safer first option for treating a blistering skin condition Signal - Doxycycline may be a safer first option for treating a blistering skin condition Dissemination Centre Discover Portal NIHR DC Discover Doxycycline may be a safer first option for treating a blistering skin condition Published on 4 July 2017 Doxycycline (an established antibiotic) may be a safer first option than the standard steroid treatment for people with the autoimmune skin condition bullous pemphigoid (...) . The condition causes severe, itchy blistering. This NIHR-funded study showed that people started on doxycycline were 19% less likely to have severe, life-threatening or fatal events during the next 12 months than those who started a steroid (prednisolone). Blister control was considered acceptable for both treatments (74% treatment success with doxycycline at six weeks compared to 91% with a steroid). Whole-body steroid cream treatment might give better results, but is not always practical. Oral steroids

NIHR Dissemination Centre2018

2. Doxycycline

Doxycycline Top results for doxycycline - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for doxycycline The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

3. Doxycycline may be a safer first option for treating a blistering skin condition

Doxycycline may be a safer first option for treating a blistering skin condition NIHR DC | Signal - Doxycycline may be a safer first option for treating a blistering skin condition Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Doxycycline may be a safer first option for treating a blistering skin condition Published on 4 July 2017 Doxycycline (an established antibiotic) may be a safer first option than the standard steroid treatment for people with the autoimmune skin (...) condition bullous pemphigoid. The condition causes severe, itchy blistering. This NIHR-funded study showed that people started on doxycycline were 19% less likely to have severe, life-threatening or fatal events during the next 12 months than those who started a steroid (prednisolone). Blister control was considered acceptable for both treatments (74% treatment success with doxycycline at six weeks compared to 91% with a steroid). Whole-body steroid cream treatment might give better results

NIHR Dissemination Centre2018

4. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. BACKGROUND: Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids. METHODS: We did a pragmatic, multicentre, parallel-group (...) randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3-9, 10-30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were

Lancet2017

5. A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BL

A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BL A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids (...) and Tetracyclines (BLISTER) Trial Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The study found that a strategy of starting bullous pemphigoid patients on doxycycline is non

NIHR HTA programme2017

6. Azithromycin versus Doxycycline for Chlamydia.

Azithromycin versus Doxycycline for Chlamydia. Azithromycin versus Doxycycline for Chlamydia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27144856 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 5;374(18):1787. doi: 10.1056/NEJMc1600830. Azithromycin versus Doxycycline for Chlamydia. , , . Comment on [N Engl J Med. 2015] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27144856 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments

NEJM2016

7. Azithromycin versus Doxycycline for Chlamydia.

Azithromycin versus Doxycycline for Chlamydia. Azithromycin versus Doxycycline for Chlamydia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27144857 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 5;374(18):1786. doi: 10.1056/NEJMc1600830#SA1. Azithromycin versus Doxycycline for Chlamydia. 1 . 1 University of California, San Francisco, San Francisco, CA julius.schachter@ucsf.edu. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2015] PMID: 27144857 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances

NEJM2016 Full Text: Link to full Text with Trip Pro

8. Azithromycin versus Doxycycline for Chlamydia.

Azithromycin versus Doxycycline for Chlamydia. Azithromycin versus Doxycycline for Chlamydia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27144858 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 5;374(18):1786-7. doi: 10.1056/NEJMc1600830#SA2. Azithromycin versus Doxycycline for Chlamydia. 1 , 2 . 1 Helios St. Elisabeth Hospital, Oberhausen, Germany alexander.kreuter@helios-kliniken.de. 2 University of Cologne, Cologne, Germany. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2015] PMID: 27144858 DOI: [Indexed

NEJM2016 Full Text: Link to full Text with Trip Pro

9. Doxycycline

Doxycycline USE OF DOXYCYCLINE IN PREGNANCY 0344 892 0909 USE OF DOXYCYCLINE IN PREGNANCY (Date of issue: June 2012 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Doxycycline is a broad spectrum tetracycline antibiotic which is also used in the prophylaxis of malaria and as an adjunct to quinine (...) in the treatment of falciparum malaria. Exposure to doxycycline in early pregnancy has not been firmly associated with any specific malformations but its use in the second or third trimester can cause discolouration of the teeth. During pregnancy, travel to areas where malaria is endemic should be avoided wherever possible. If travel to such areas is unavoidable, chloroquine and proguanil are the preferred antimalarials to use during pregnancy. Doxycycline is best avoided for antimalarial prophylaxis during

UK Teratology Information Service2014

10. Acticlate Tablets (Doxycycline hyclate)

Acticlate Tablets (Doxycycline hyclate) Drug Approval Package: Brand Omtryg capsules NDA 204977 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Acticlate Tablets (Doxycycline hyclate) Company: Aqua Pharmaceuticals Application No.: 205931 Approval Date: 7/25/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2014

11. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial.

Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. BACKGROUND: Doxycycline inhibits formation and progression of abdominal aortic aneurysms (AAAs) in preclinical models of the disease, but it is unclear whether and how this observation translates to humans. OBJECTIVE: To test whether doxycycline inhibits AAA progression in humans. DESIGN: Randomized, placebo-controlled, double-blind trial. (Dutch Trial Registry: NTR 1345) SETTING: 14 Dutch hospitals. PATIENTS: 286 (...) patients with small AAAs between October 2008 and June 2011. INTERVENTION: Daily dose of 100 mg of doxycycline (n = 144) or placebo (n = 142) for 18 months. MEASUREMENTS: The primary outcome measure was aneurysm growth at 18 months, as estimated by repeated single-observer ultrasonography. Secondary outcomes included growth at 6 and 12 months and the need for elective surgery. RESULTS: Mean aneurysm diameter (approximately 43 mm) and other baseline characteristics were similar in both groups

Annals of Internal Medicine2013

12. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial.

Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. BACKGROUND: Melioidosis, an infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, is difficult to cure. Antimicrobial treatment comprises intravenous drugs for at least 10 days, followed by oral drugs for at least 12 weeks. The standard oral regimen based (...) on trial evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline. This regimen is used in Thailand but is associated with side-effects and poor adherence by patients, and TMP-SMX alone is recommended in Australia. We compared the efficacy and side-effects of TMP-SMX with TMP-SMX plus doxycycline for the oral phase of melioidosis treatment. METHODS: For this multi-centre, double-blind, non-inferiority, randomised placebo-controlled trial, we enrolled patients (aged ≥15 years) from five

Lancet2013 Full Text: Link to full Text with Trip Pro

14. Doxycycline therapy for leptospirosis.

Doxycycline therapy for leptospirosis. Doxycycline therapy for leptospir... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1984 ) Volume: 100 , Issue: 5 , Pages: 696-698 PubMed: Available from or Find this paper at: Abstract To study antibiotic efficacy, 29 patients with leptospirosis were treated in a randomized, double-blinded fashion with doxycycline, 100 mg orally twice a day (...) , or placebo. Therapy was given for 7 days in a hospital, and patients were followed for 3 weeks afterwards. Duration of illness before therapy and severity of illness were the same in both groups. Doxycycline reduced the duration of illness by 2 days and favorably affected fever, malaise, headache, and myalgias. Treatment prevented leptospiruria and had no adverse effects. Doxycycline is effective in therapy for patients with leptospirosis. Author-supplied keywords Related papers Matthew E Griffith

Annals of Internal Medicine2013

16. Doxycycline ineffective for osteoarthritis of the knee or hip

Doxycycline ineffective for osteoarthritis of the knee or hip PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Doxycycline ineffective for osteoarthritis of the knee or hip Clinical question How effective is doxycycline for osteoarthritis (OA) of the knee or hip? Bottom line Compared to placebo, there is minimal or no symptomatic benefit (pain reduction and improved physical function (...) ) with doxycycline treatment. The small benefit observed in joint space narrowing is of questionable clinical relevance and outweighed by safety issues. Doxycycline should therefore not be recommended for the treatment of osteoarthritis of the knee or hip. Caveat The trial was designed to detect differences in joint space narrowing rather than differences in clinical outcomes. No threshold for the level of knee pain was used for inclusion and the average level of knee pain was low at baseline, leaving little

Cochrane PEARLS2011

17. Subantimicrobial-Dose Doxycycline (SDD) Periodontal therapy reduces serum biomarkers of systemic inflammation and can increase high-density lipoprotein

Subantimicrobial-Dose Doxycycline (SDD) Periodontal therapy reduces serum biomarkers of systemic inflammation and can increase high-density lipoprotein UTCAT856, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Subantimicrobial-Dose Doxycycline (SDD) Periodontal Therapy Reduces Serum Biomarkers Of Systemic Inflammation And Can Increase High-Density Lipoprotein Clinical Question In post-menopausal women with chronic (...) periodontitis does a systemic dose of Doxycycline in comparison to placebo increase high-density lipoprotein (HDL) levels? Clinical Bottom Line In post-menopausal women with chronic periodontitis Subantimicrobial-Dose Doxycycline Periodontal therapy reduces serum biomarkers of systemic inflammation and among women more than five years post-menopausal, the SDD regimen elevated their level of high-density lipoprotein (HDL) cholesterol. (See Comments on the CAT below) Best Evidence (you may view more info

UTHSCSA Dental School CAT Library2011

18. Systematic review: Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than mefloquine

Systematic review: Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than mefloquine Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than mefloquine | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than

Evidence-Based Nursing (Requires free registration)2010

19. A randomized trial of doxycycline for Mansonella perstans infection.

A randomized trial of doxycycline for Mansonella perstans infection. 19812401 2009 10 08 2009 10 16 2017 02 20 1533-4406 361 15 2009 Oct 08 The New England journal of medicine N. Engl. J. Med. A randomized trial of doxycycline for Mansonella perstans infection. 1448-58 10.1056/NEJMoa0900863 Mansonella perstans infection is common in areas of Africa where Wuchereria bancrofti, a causative agent of lymphatic filariasis, is endemic. M. perstans is refractory to standard antifilarial therapies (...) . The recent discovery of bacterial endosymbionts (e.g., wolbachia) in most filarial species, including M. perstans, provides new therapeutic options for reducing microfilaremia. In an open-label, randomized trial, we recruited subjects with M. perstans microfilaremia, with or without concomitant W. bancrofti infection, from four villages in Mali and randomly assigned them to receive doxycycline, at a dose of 200 mg daily for 6 weeks (106 subjects), or no treatment (110). At 6 months, subjects who were

NEJM2009 Full Text: Link to full Text with Trip Pro

20. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial

Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial 18567539 2008 07 18 2008 09 19 2014 08 15 1474-4422 7 8 2008 Aug The Lancet. Neurology Lancet Neurol Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. 690-5 10.1016/S1474-4422(08)70119-4 Use of intravenous penicillin and ceftriaxone to treat Lyme (...) neuroborreliosis is well documented, although oral doxycycline could be a cost-effective alternative. We aimed to compare the efficacy of oral doxycycline with intravenous ceftriaxone for the treatment of Lyme neuroborreliosis. From April, 2004, to October, 2007, we recruited consecutive adult patients from nine hospitals in southern Norway into a non-inferiority trial. Inclusion criteria were neurological symptoms suggestive of Lyme neuroborreliosis without other obvious causes, and presence of any

EvidenceUpdates2008